1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Cancer Drug News 05 OCTOBER 2015

Cancer Drug News 05 OCTOBER 2015

  • October 2015
  • -
  • Espicom Business Intelligence
  • -
  • 8 pages

Industry Trend Analysis - Roche's Entry Into Checkpoint Inhibition Market Imminent
Industry Brief - Phase II Xtandi Data Demonstrate Potential Advantages Of Genomic Profiling Assay
Industry Brief - R-Pharm US Acquires Ixempra From BMS
Industry Brief - Janssen's Daratumumab Accepted For CHMP Accelerated Assessment
Industry Trend Analysis - Wave Of Positive Anti-CSC Data Crucial To Rebuilding Confidence
Industry Brief - Data Support Continued Development Of Cyramza In Urothelial Carcinoma
Industry Brief - First Data From The Prostate Cancer Registry Released At ECC 2015
Industry Brief - Tasquinimod Does Not Improve OS In mCRPC
Industry Brief - Roche's anti-PDL1 Achieves Positive Results In Phase II mUC Study
Industry Brief - Blueprint Medicines Receives FDA ODD For HCC Candidate
Industry Brief - Merck/DNAtrix Enter Phase II Immuno-oncology Collaboration
Industry Brief - FDA Grants Avelumab ODD For Merkel Cell Carcinoma
Industry Brief - Opdivo+Yervoy Regimen Gains FDA Approval For BRAF V600 Wild-Type MM
Industry Trend Analysis - Novartis Deal Offers XOMA Recovery Opportunity
Industry Brief - Clovis Achieves US/EU Regulatory Milestones For Rociletinib
Industry Trend Analysis - Companion Diagnostic Not Enough To Secure Avelumab Market Share
Industry Brief - Yondelis Approved In Japan For STS

Table Of Contents

Cancer Drug News 05 OCTOBER 2015

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung ...

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

  • $ 6995
  • Industry report
  • November 2016
  • by GlobalData

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident ...

2017-2021 US Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Suppliers

2017-2021 US Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Suppliers

  • $ 6400
  • Industry report
  • February 2017
  • by Venture Planning Group

Complete report $9,800.  DataPack (test volumes, sales forecasts, supplier shares) $6,400. Highlights Comprehensive 620-page analysis of the US tumor marker testing market.Major issues pertaining to the ...


Download Unlimited Documents from Trusted Public Sources

Cancer Statistics in Australia - Forecast

  • February 2017
    4 pages
  • Cancer  

    Ovarian Cancer  

  • Australia  

    Oceania  

View report >

Cancer Statistics in the UK

  • February 2017
    11 pages
  • Cancer  

  • United Kingdom  

    Australia  

    Denmark  

View report >

Cancer Statistics in the UK

  • February 2017
    18 pages
  • Cancer  

  • United Kingdom  

View report >

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.